Weight for It…

“Novo Holdings, the parent company of Danish pharma giant Novo Nordisk, agreed to buy New Jersey-based contract manufacturer Catalent for around $16.5 billion in cash. This deal is about boosting production of Wegovy, the anti-obesity drug whose demand has far outpaced supply.” So now we’re over-consuming anti-obesity drugs?